A common therapeutic strategy to combat human cancer is the use of combinations of drugs, each targeting different cellular processes or vulnerabilities. Recent studies suggest that addition of an MCL-1 inhibitor to such anticancer drug treatments could be an attractive therapeutic strategy. Thus, it is of great interest to understand whether combinations of conventional anticancer drugs with an MCL-1 inhibitor will be tolerable and efficacious. In order to mimic the combination of MCL-1 inhibition with other cancer therapeutics, we treated Mcl-1 +/ − heterozygous mice, which have a~50% reduction in MCL-1 protein in their cells, with a broad range of chemotherapeutic drugs. Careful monitoring of treated mice revealed that a wide range of chemotherapeutic drugs had no significant effect on the general well-being of Mcl-1 +/ − mice with no overt damage to a broad range of tissues, including the haematopoietic compartment, heart, liver and kidney. These results indicate that MCL-1 inhibition may represent a tolerable strategy in cancer therapy, even when combined with select cytotoxic drugs.
Inefficient activation of apoptosis is considered to be responsible (at least in part) for the resistance of tumour cells to a broad range of anticancer treatments. [1] [2] [3] [4] The mitochondrial apoptotic pathway is regulated by the pro-apoptotic multi-BH (BCL-2 homology) domain proteins BAX, BAK and BOK, the pro-apoptotic BH3-only proteins BAD, BIK, BID, BIM, BMF, NOXA, HRK, PUMA and the anti-apoptotic BCL-2 proteins BCL-2, BCL-XL, BCL-W, A1, MCL-1 via protein-protein interactions. 5, 6 Depending on their relative expression levels in cancers, different anti-apoptotic BCL-2 proteins represent promising therapeutic targets.
MCL-1 is unique among the anti-apoptotic BCL-2 proteins as it is important for the survival of many cell types. Constitutive loss of MCL-1 causes embryonic lethality (E3.5). 7 Tissue-specific ablation Mcl-1 (both alleles) in adult mice demonstrated that MCL-1 is essential for the survival of haematopoietic stem/progenitor cells, 8 B and T cells, 9 plasma cells, 10 neutrophils, 11 basophils, 12 mast cells, 12 cardiomyocytes 13, 14 and hepatocytes. 15, 16 The Mcl-1 gene locus is amplified in many (at least 10%) human cancers, including acute myeloid leukaemia (AML), 17 mantle cell lymphoma (MCL), 18 diffuse large B-cell lymphoma, nonHodgkin's lymphoma (HL) 19 and multiple myeloma (MM). 20 Genetic studies using mouse models revealed that inducible loss of MCL-1, in the case of c-MYC-driven lymphomas even loss of one Mcl-1 allele, resulted in efficient killing of cancers. [21] [22] [23] [24] Conversely, overexpression of MCL-1 enhanced c-MYC-and v-ABL-driven lymphoma and plasmacytoma development, respectively. [25] [26] [27] Hence, it was hypothesised that inhibitors of MCL-1 (BH3 mimetics) may efficiently kill tumour cells. Excitingly, a potent and highly specific MCL-1 inhibitor, S63845, was recently developed and first evaluations demonstrated great potential against diverse tumours and tolerability in preclinical models of cancer. 28 A common strategy for cancer therapy is the combinatorial use of several drugs targeting different cellular pathways and vulnerabilities.
1,2 Thus, it is important to understand whether combined therapies including conventional anticancer drugs and MCL-1 inhibitors are tolerable and efficacious. Notably, our laboratory has recently shown that loss of one allele of Mcl-1 severely compromised haematopoietic recovery after myeloablative challenge. 29 This suggested that a combination of MCL-1 inhibitors and DNA-damaging drugs may cause unacceptable toxicity. The MCL-1 inhibitor S63845 is unfortunately not yet available at an affordable cost for large scale in vivo testing. Therefore, in order to mimic the combination of drug-mediated loss of MCL-1 function with chemotherapeutics, we exposed Mcl-1 +/ − mice, which have a~50% reduction in MCL-1 protein, to a broad range of drugs at clinically relevant doses. Upon treatment, the health of the Mcl-1 +/ − mice was monitored with specific attention to changes in the haematopoietic compartment. The results of these studies provide important information for the safety of MCL-1 Inhibitors when used in clinical combination therapies for cancer.
Results
Reduction in MCL-1 causes a significant albeit minor reduction in certain blood cell subsets. MCL-1 is essential for the survival of a many cell types. [8] [9] [10] [11] [12] [13] [14] [15] [16] Here we show that organism-wide constitutive loss of a single Mcl-1 allele reduces MCL-1 protein levels by 30-50%, depending on the cell type ( Figure 1a and Supplementary Figure S1a) . The levels of other anti-apoptotic (BCL-2 and BCL-XL) or proapoptotic (BIM) BCL-2 family members were comparable across several haematopoietic cell subsets between
Mcl-1
+/ − and wild-type mice ( Figure 1a and Supplementary Figure S1a ). In Mcl-1 +/ − mice, the lymphoid and other haematopoietic cell types were reduced to a significant, albeit relatively minor, extent compared with wild-type mice ( Figure 1 and Supplementary Figure S1 ). The numbers of all cell subsets analysed were reduced to a similar extent (Supplementary Figure S1b) , consistent with prior observations that MCL-1 is essential for the survival of several haematopoietic cell types. [8] [9] [10] [11] [12] Although the Mcl-1 +/ − mice presented with a minor reduction in red blood cells (RBCs) compared with wild-type controls (Figure 1b ), they were not anaemic as shown by their normal haemoglobin content (HGB) and haematocrit (HCT) (Figure 1b) . This is likely due to compensatory processes resulting in a slight increase in median corpus volume and median haemoglobin content of their RBCs (Supplementary Figure S1c) . Figure S1e) confirmed a small reduction in overall cellularity in these tissues in Mcl-1 +/ − mice, but no severe cytopenia was ever observed. Collectively, these results show that loss of one allele of Mcl-1 causes a significant, albeit minor, reduction in several haematopoietic cell subsets, even in the absence of stress, but does not lead to compensatory changes in the levels of other BCL-2 protein family members.
Reduction in MCL-1 levels does not negatively impact on the general health of mice treated with standard chemotherapeutics. A common side effect of standard chemotherapy in clinical settings is bone marrow cytopenia with depletion of cycling immature progenitors, lymphocytes and other blood cells. We believe that the 30-50% reduction in MCL-1 protein levels, which is not compensated by readily detectable changes in the expression of other BCL-2 family members, in Mcl-1 +/ − mice is a reasonable mimic of drugmediated inhibition of MCL-1. Of note, the reduction in leukocytes in Mcl-1 +/ − mice observed here ( Figure 1 ) is similar to that detected in wild-type mice treated with the MCL-1 inhibitor S63845. 28 To identify potential toxic side effects caused by the combination of reduction/inhibition of MCL-1 protein and standard chemotherapy, Mcl-1 +/ − and, as a control, wildtype mice were treated with seven clinically relevant chemotherapeutic drugs. These included 5-FU (fluorouracil and adrucil), cytarabine (cytosine arabinoside and ara-C), hydroxyurea (hydroxycarbamide, hydrea, litalir and droxia), etoposide (etopophos and toposar), doxorubicin (adriamycin, doxil, caelyx and myocet), dexamethasone and paclitaxel (taxol, abraxane and onxol). These drugs were used at doses and schedules adjusted to conventional clinical protocols for the treatment of leukaemia and lymphoma patients (http://www. fda.gov/RegulatoryInformation/Guidances, Supplementary Figure S2 ).
Although high doses of 5-FU (150 mg/kg) caused the death of Mcl-1 +/ − but not wild-type mice ( Figure 2b and Delbridge et al. 29 ), clinically relevant (more moderate: 100 mg/kg) doses of 5-FU were tolerated in both Mcl-1 +/ − and wild-type mice (Figures 2b-e) . Similar results were obtained with moderate doses of cytarabine, hydroxyurea, etoposide, doxorubicin, dexamethasone and paclitaxel. We observed no obvious abnormalities in behaviour, breathing, food intake or weight loss, as general markers for normal function of the neuronal, cardiovascular and digestive systems, or anaemia ( Figure 2e ). These results show that the chemotherapeutic drugs tested did not cause overt pathology in mice with reduced MCL-1 levels.
Reduction in MCL-1 levels only moderately exacerbates the haematopoietic cytopenia caused by treatment with drugs that interfere with DNA synthesis. To test potential toxicity to the haematopoietic compartment exerted by anticancer drugs that interfere with DNA synthesis combined with reduced MCL-1 expression, Mcl-1 +/ − and wild-type mice were treated with clinically relevant doses of 5-FU, cytarabine and hydroxyurea (Supplementary Figure S2) . These drugs were shown to activate the mitochondrial apoptotic cell death pathway mainly by inducing DNA damage during DNA replication as a result of interfering with the supply of metabolites needed for DNA synthesis. 5-FU inhibits thymidylate synthase and thereby decreases the supply of thymidine. Hydroxyurea suppresses ribonucleotide reductase, thereby decreasing the production of all deoxyribonucleotides required for DNA synthesis. Cytarabine consists of a cytosine base linked to an arabinose sugar, which is rapidly converted into the anti-metabolite cytosine arabinose triphosphate. Owing to its similarity to deoxycytidine triphosphate cytosine arabinose triphosphate is incorporated into DNA during synthesis, thereby causing a stop in DNA replication (http://www.fda.gov).
Treatment of mice with moderate doses of 5-FU, cytarabine or hydroxyurea resulted in mild leukopenia (low WBC count) ( Figure S3d) . Notably, only treatment with hydroxyurea resulted in the depletion of granulocytes in the bone marrow, and this was comparable between Mcl-1 +/ − and wild-type mice (Figure 3d ). Treatment with 5-FU, cytarabine and hydroxyurea caused only a relatively mild depletion of T-cell populations in the thymus, including CD4-CD8-(double negative = DN) progenitors, CD4 +CD8+ (double positive = DP) precursors as well as CD4 +CD8-and CD4-CD8+ mature T cells (Figure 3f ).
In the spleen, only treatment with hydroxyurea resulted in a substantial loss of B and T lymphocytes and myeloid cells (monocytes/macrophages, granulocytes), and this was comparable between Mcl-1 +/ − and wild-type mice. Mcl-1 +/ − and wild-type mice treated with cytarabine had an abnormally enlarged spleen after 7 days, accompanied by an increase in both lymphoid as well as myeloid cells. Treatment with 5-FU caused a reduction in splenic monocytes/macrophages in both Mcl-1 +/ − and wild-type mice and also a minor reduction in splenic B cells (Supplementary Figure S3c) . Importantly, numbers of all haematopoietic cell subsets examined normalised in all Mcl-1 +/ − and wild-type mice and no cytopenia was observed in H&E-stained sections of the sternum (Supplementary Figure S3e ) and spleen (Supplementary Figure S3f) at the end of treatment.
Collectively, these findings reveal that 5-FU, cytarabine and hydroxyurea were all more toxic in Mcl-1 +/ − mice compared with wild-type controls, but both groups of animals could readily recover from the transient haematopoietic cytopenia. +/ − and wild-type (wt) mice were treated with clinically relevant regimens of chemotherapeutic drugs, including 5-fluorouracil (5-FU), hydroxyurea, cytarabine, etoposide, doxorubicin, dexamethasone and paclitaxel. Upon treatment, the general health, including weight and signs of anaemia, were carefully monitored for a minimum of 21 days. Furthermore, the haematopoietic cell subset composition was analysed on days 0, 4, 7, 10, 14 and 21-35 days post-treatment. Peripheral blood samples were analysed using FACS and ADVIA, and the absolute numbers of white blood cells, RBCs, lymphocytes and platelets were determined. Haemoglobin content and RBC quality (median corpuscular volume and haemoglobin content in RBC) were also assessed. At day 7 post-treatment, a group of mice from each treatment cohort was killed for a detailed analysis of their haematopoietic system and other tissues. Supplementary Figures S4a and b) . Mcl-1 +/ − and wild-type mice both presented with anaemia shortly after treatment (Figure 4b and Supplementary Figures S4c and d) . Neither doxorubicin nor etoposide had a significant impact on platelet numbers in Mcl-1 +/ − or wild-type mice (Supplementary Figure S4b ). Mcl-1 +/ − and wild-type mice both recovered from the drug-induced cytopenia and anaemia within 10-14 days, albeit with a marked delay seen in Mcl-1 +/ − mice. Consistent with the loss of peripheral WBCs after treatment with etoposide or doxorubicin, severe bone marrow cytopenia was seen in both Mcl-1 +/ − and wild-type mice (Figures 4c-e) . FACS analysis revealed that pro-B/pre-B, immature, transitional and mature B cells as well as monocytes and macrophages but not granulocytes were significantly depleted in drug-treated animals (Figures 4d and e) . For all cell populations, the reduction was found to be more pronounced in Mcl-1 +/ − mice compared with wild-type controls. Treatment with doxorubicin also caused a substantial loss of thymic T cells, including DN progenitors, DP precursors and CD4+ as well as CD8+ mature single positive T cells in both Mcl-1 +/ − and wild-type mice (Figure 4f, left panel) . The cytotoxic effects of etoposide on thymic T lymphoid cells 7 days post-treatment, were less pronounced compared with those exerted by doxorubicin (Figure 4f, right panel) . Notably, treatment with doxorubicin resulted in a marked loss of B, T and myeloid cells (monocytes/macrophages and granulocytes) in the spleen, which was comparable between Mcl-1 +/ − and wild-type mice.
+/ − and wild-type mice treated with etoposide had a greatly enlarged spleen after 7 days, and this was accompanied by a pronounced increase in lymphoid cells (Supplementary Figure S4e ). The Mcl-1 +/ − and wild-type mice both recovered from the doxorubicin or etoposide-induced cytopenia ( Supplementary Figures S4f and g ).
These results show that Mcl-1 +/ − mice can tolerate clinically relevant doses of doxorubicin and etoposide.
Reduction in MCL-1 levels does not drastically exacerbate haematopoietic cytopenia caused by non-DNAdamaging chemotherapeutic drugs. In order to gain a more comprehensive insight into possible combinatorial toxicities caused by reduction in MCL-1 levels with standard anticancer drugs, we also examined the impact of chemotherapeutics that do not induce DNA damage. The steroid dexamethasone and the tubulin toxin paclitaxel both activate the mitochondrial apoptotic pathway mainly through the induction of the pro-apoptotic BH3-only proteins BIM and, in the case of dexamethasone, also PUMA. [34] [35] [36] Analysis of the blood revealed a significant decrease in WBCs (Supplementary Figure S5a (Figures 5c-e) . No significant differences between Mcl-1 +/ − and wild-type mice were observed. As expected, 37 treatment with dexamethasone rapidly (within 48 h) caused a depletion of thymic T cells, mainly affecting the CD4+CD8+ DP precursors (Supplementary Figure S5f) . Mcl-1 +/ − and wild-type mice both recovered from this toxic effect on T cells and no severe reduction was detectable 7 days after drug treatment (Figure 5f ).
Treatment with paclitaxel also resulted in a depletion of splenic B and T cells 7 days post-treatment, and this was slightly more pronounced in mice with reduced MCL-1 (Supplementary Figure S5c) . Histological analysis of the sternum and spleen revealed that all animals had fully recovered from their transient haematopoietic cytopenia by the end of the treatment (Supplementary Figures S5d  and e) .
These results show that dexamethasone and paclitaxel, anticancer drugs that do not induce DNA damage, cause severe transient depletion of WBCs and RBCs in Mcl-1 +/ − and wild-type mice, but both sets of animals could readily recover.
Reduction in MCL-1 levels does not cause cardio-, nephro-or hepato-toxicity. Apart from the severe toxicity of chemotherapy on haematopoietic cells, resulting in transient anaemia and immunodeficiency, cardio-toxicity has been frequently reported for the treatment with 5-FU, doxorubicin, paclitaxel and dexamethasone (http://www.fda. gov/RegulatoryInformation/Guidances). Hydroxyurea has been shown to cause hepato-and nephro-toxicity. Notably, Reduced MCL-1 combined with cancer drugs K Brinkmann et al complete tissue-specific loss of MCL-1 was shown to cause severe, even fatal, damage to the heart 13,14 and liver. 15, 16 Hence, reductions in MCL-1 expression may result in even more severe cardio-, hepato-and nephro-toxicity upon treatment with anticancer drugs.
To explore this, we treated Mcl-1 +/ − and wild-type mice with clinically relevant regimes of the chemotherapeutic drugs mentioned above, and tested whether Mcl-1 +/ − mice were more severely affected. Careful monitoring of the treated mice, did not reveal a severe impact on their general well-being (including physical activity, breathing, food intake and excretion). Detailed histological examination did not reveal detectable damage to the heart, kidney and liver (Figures 6a-c and Supplementary Figures S6a-c) in drug-treated wild-type and Mcl-1 +/ − mice. These results show that a reduction in MCL-1 expression does not cooperate with commonly used anticancer drugs to cause damage to the heart, liver or kidney. Discussion MCL-1 represents a promising target for anticancer therapy. [17] [18] [19] [20] [21] 23 Excitingly, first preclinical studies with the recently described highly specific MCL-1 inhibitor, S63845, have shown that this drug is effective and tolerable in diverse murine cancer models. 28 However, several haematological and solid cancers (e.g., a subset of human CML, breast cancer and melanoma cell lines tested), showed only moderate responses to S63845 as a single agent. Interestingly, many of these tumour-derived cell lines were potently killed by combinations of S63845 with other anticancer drugs. 11 However, we found only a minor increase in BCL-2 in peripheral blood monocytes/macrophages in Mcl-1 +/ − mice but no increase in bone marrow resident macrophages. This indicates that only complete loss of MCL-1 selects for compensatory changes in the expression of other BCL-2 family members. Thus, we believe that our toxicity analyses in Mcl-1 +/ − mice are a fair representation of the combined treatment of chemotherapeutic drugs with the MCL-1 inhibitor S63845. Admittedly, preclinical and future clinical studies using MCL-1 inhibitors combined with standard chemotherapeutic drugs are required to establish efficient, non-toxic drug combinations.
Our findings show that anti-metabolic DNA-damaging drugs or drugs that activate the mitochondrial apoptotic pathway without engaging the DNA damage response machinery cause more severe haematopoietic cell depletion in Mcl-1 +/ − compared with wild-type mice. However, both cohorts of animals were able to fully recover.
As MCL-1 has an essential role in the survival of developing B and T cells, caution has to be taken when combining an MCL-1 inhibitor with drugs that impact on lymphocyte survival. 38, 39 Accordingly, for several of the anticancer drugs tested, a mild but significant exacerbation in the depletion of peripheral lymphocytes was seen in Mcl-1 +/ − compared with wild-type mice. Specifically, Mcl-1 +/ − mice exhibited a more profound depletion of several B-cell subsets in the bone marrow upon treatment with DNA-damaging drugs compared with wild-type mice. DNA damage results in the activation of ATM/ATR and ultimately in p53-mediated induction of the proapoptotic BH3-only proteins PUMA 40 and NOXA. 41 NOXA is a specific and highly potent inhibitor of MCL-1, whereas PUMA binds and inhibits all pro-survival BCL-2 family members, including MCL-1. 42 Notably, NOXA-mediated inhibition of MCL-1 has been shown to be a critical determinant of the response of certain lymphoid cancers (e.g., CLL, HL, MM and MCL) to several chemotherapeutics, including DNA-damaging drugs. [43] [44] [45] [46] This may be attributed to NOXA-mediated increase of MCL-1 protein turnover. 47 Accordingly, we found that cells with decreased MCL-1 levels were more susceptible to DNA damage-induced apoptosis compared with control cells.
Our study revealed that there was no increased vulnerability of lymphoid cells in Mcl-1 +/ − mice to killing induced by treatment with dexamethasone or paclitaxel. Similar to DNA damage-inducing anticancer drugs, dexamethasone and paclitaxel are both reported to induce the mitochondrial apoptotic pathway. However, in contrast to DNA damageinducing drugs, they act mainly through the induction of the pro-apoptotic proteins BIM and PUMA via a p53-independent pathway but not through p53-mediated activation of NOXA and PUMA. [34] [35] [36] Although NOXA is only capable to bind and inhibit MCL-1 (and enhance its ubiquitin/proteasome-dependent degradation), BIM and PUMA can bind and inhibit all prosurvival BCL-2-family members, 42 but they do not enhance MCL-1 degradation. Thus, dexamethasone and paclitaxel induced BIM (and PUMA) mediated apoptosis appears to be less dependent on specific antagonism of MCL-1 compared with cell death pathways that are driven to a substantial extent by NOXA. This may explain why reductions in MCL-1 protein levels impact more substantially on cell killing induced by DNA-damaging drugs than dexamethasone or paclitaxel.
We observed no increased toxicity of the anticancer drugs tested in the heart, liver and kidneys in Mcl-1 +/ − mice compared with wild-type controls. This is surprising given that complete loss of MCL-1 caused substantial, sometimes fatal, damage to these tissues. [13] [14] [15] [16] These seemingly discrepant findings may be reconciled by assuming that MCL-1 must be completely removed to cause the death of cardiomyocytes and liver cells, even when animals are exposed to cytotoxic drugs. This is encouraging for the clinical testing of MCL-1 inhibitors, as treatment with such agents will only cause transient and partial inhibition of MCL-1 function.
Taken together, our studies suggest that combinations of MCL-1 inhibitors with diverse conventional anticancer drugs (including DNA damage-inducing drugs) may be tolerable. However, thorough preclinical drug dose escalation studies with particularly careful monitoring of the haematopoietic compartment are imperative before such treatments can be tested in cancer patients. Blood analysis. Mandible bleeds were taken at the indicated time points and haemogram analysis was performed using the ADVIA system (Siemens Healthcare Pty Erlangen, Germany). FACS analysis was performed as described below.
Flow cytometric analysis. Thymus, spleen and bone marrow cells were harvested and single-cell suspensions were prepared. Cells were counted using the CasyCell Counter (Schärfe System GmbH, Reutlingen, Germany). The numbers of haematopoietic cell subsets were determined by flow cytometric analysis using a FortessaX20 flow cytometer (BD Biosciences, San Jose, CA, USA). Cells were stained for the following haematopoietic cell subset-specific surface markers: B220 (RA3-6B2), IgM (5.1), CD4 (YTA3.2.1), CD8 (YTS169), GR-1 (RB6-8C5), MAC-1 (MI/70). Erythroid cells were removed from mandible bleeds using RBC lysis buffer before flow cytometric analysis. Single-cell suspensions were incubated with fluorochrome-conjugated monoclonal antibodies for 30 min on ice in buffered saline supplemented with 5% foetal bovine serum and 10% 24G2 hybridoma supernatant (antibody against FcγR) to block nonspecific antibody binding. After staining, cells were washed twice with buffered saline supplemented with 5% foetal bovine serum and analysed in the same buffer supplemented with propidium iodide (PI, 2 μg/ml). Cell doublets and dead cells were identified and gated out using FSC-H/FSC-A and PI staining analysis, respectively. Intracellular staining was performed using the eBioscience (San Diego, CA, USA) FoxP3 Transcription Factor Staining Buffer Set according to the manufacturer's instructions using the following antibodies: anti-MCL-1 (clone 19C4-15, WEHI, Pakville, VIC, Australia), 49 anti-BCL-XL (clone E18,
